Erratum to Platinum-based chemotherapy in triple-negative advanced breast cancer (Breast Cancer Res Treat, (2014), 146, (567-572), 10.1007/s10549-014-3033-4);Platinum-based chemotherapy in triple-negative advanced breast cancer

Breast Cancer Research and Treatment

Volumn 146, Issue 3, 2014, Pages 567-572

  Villarreal Garza, Cynthia ^a,b   Khalaf, Daniel ^c   Bouganim, Nathaniel ^c   Clemons, Mark ^c   Peña Curiel, Omar ^a   Baez Revueltas, Berenice ^d   Kiss, Alexander ^b   Kassam, Farah ^e   Enright, Katherine ^e   Verma, Sunil ^b   Pritchard, Kathleen ^b   Myers, Jeff ^f   Dent, Rebecca ^b,g  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d INSTITUTO TECNOLÓGICO AUTÓNOMO DE MÉXICO   (Mexico)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f CREDIT VALLEY HOSPITAL   (Canada)

^g DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Metastatic triple negative breast cancer; Platinum based chemotherapy; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; ADVANCED CANCER; ARTICLE; BREAST METASTASIS; CANADA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; META ANALYSIS; NEOPLASM METASTASIS; PATHOLOGY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; DISEASE-FREE SURVIVAL; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PLATINUM; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907598021     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3345-z     Document Type: Erratum

References (30)

1. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434 (Pubitemid 47219710)
2. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657 (Pubitemid 46631305)
3. Kassam F, Enright K, Dent R et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9:29-33
4. Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638-2645
5. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685 (Pubitemid 41170290)
6. Toft DJ, Cryns VL (2011) Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 25:199-211
7. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819 (Pubitemid 39331153)
8. Kim T, Lee H, Han S et al (2010) The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. J Clin Oncol 28:1071
9. Koshy N, Quispe D, Shi R et al (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19:246-248
10. Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847-1852
11. Staudacher L, Cottu PH, Dieras V et al (2011) Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22:848-856
12. Uhm JE, Park YH, Yi SY et al (2009) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124:1457-1462
13. Bhattacharyya Gs BS, Agarwal V et al (2009) Single institute phaseII study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. EJC suppl 7:18-19
14. Fan Y, Xu BH, Yuan P et al (2012) P5-19-04: Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC). Cancer Research 71:P5-19-04
15. Isakoff SJ, Goss PE, Mayer EL et al (2011) TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 29:1025
16. Wang Z, Hu X, Chen L et al (2010) Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: preliminary results report of a phase II trial. J Clin Oncol 28:1100
17. Verma S, Provencher L, Dent R (2011) Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 18:180-190
18. O'shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214
19. Baselga J, Stemmer S, Pego A et al (2011) Abstract PD01-01: cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, her2-negative (triple-negative) metastatic breast cancer: results of the randomized phase ii bali-1 trial. Cancer Res 70:PD01-01
20. Cameron D, Brown J, Dent R et al (2012) Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res 72:S6-5
21. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846-5853 (Pubitemid 44453440)
22. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790
23. Decatris MP, Sundar S, O'byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 30:53-81 (Pubitemid 38240088)
24. Khalaf D, Hilton JF, Clemons M et al (2014) Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 7:866-870
25. O'shaughnessy J, Schwartzberg LS, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29:1007
26. Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 138:783-794
27. Von Minckwitz G, Schneeweiss A, Salat C et al (2013) A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31:1004
28. Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005
29. Peddi PF, Ellis MJ, Ma C (2012) Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012:217185
30. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767